Source comparison
Thymosin Alpha-1 Chronic Fatigue: Protocol Comparison
Standard Tα1 Monotherapy 1.6mg subcutaneous twice weekly 8–12 weeks for 30% FSI reduction Th1 polarization, NK cell activation, Treg expansion Best for patients with isolated immune dysfunction and low baseline inflammation (hsCRP <3mg/L) High-Dose Tα1 3.2mg s
This comparison does not assign a generated winner or score.
- Standard Tα1 Monotherapy
- 1.6mg subcutaneous twice weekly
- 8–12 weeks for 30% FSI reduction
- Th1 polarization, NK cell activation, Treg expansion
- Best for patients with isolated immune dysfunction and low baseline inflammation (hsCRP <3mg/L)
- High-Dose Tα1
- 3.2mg subcutaneous twice weekly
- 6–10 weeks for symptom improvement
- Accelerated thymic output, faster cytokine normalization
- Reserved for severe NK depletion (<100 cells/μL) or active viral reactivation. No additional benefit in mild cases
- Tα1 + Antiviral (Valacyclovir)
- 1.6mg Tα1 twice weekly + 1g valacyclovir daily
- 10–14 weeks (viral clearance + immune rebuild)
- Simultaneous viral suppression and immune restoration
- Indicated for EBV/HHV-6 reactivation confirmed by PCR or elevated IgG titers
- Tα1 + Mitochondrial Support
- 1.6mg Tα1 twice weekly + CoQ10 200mg + NAD+ precursors
- 8–12 weeks (immune) + 4–6 weeks (energy substrates)
- Immune modulation + ATP production support
- Useful when fatigue includes post-exertional malaise (PEM) suggesting mitochondrial dysfunction